Literature DB >> 19393345

The ectopic expression of IFN regulatory factor 4-binding protein is correlated with the malignant behavior of human breast cancer cells.

Peng Li1, Zhujun Zhang, Qingliang Wang, Shuhui Li, Yang Zhang, Xiuwu Bian, An Chen, Chuanmin Hu.   

Abstract

Many proteins that are aberrantly expressed in malignant tumors play important roles in promoting tumorigenesis, metastasis and immune escape. IFN regulatory factor 4-binding protein (IBP), which is a novel PH-DH-like protein related to SWAP-70, and functions as an upstream activator of Rho GTPases. It is widely expressed in cells of the immune system and is involved in coupling activated cell receptors to downstream signaling events that mediate cell proliferation, differentiation and polarization. Although IBP was detected in human chondrosarcoma, its function in tumor cells remains unknown. In this study, newly generated monoclonal anti-IBP antibodies were employed and they detected higher level expression of IBP in some human invasive breast carcinoma tissues and in two breast cancer cell lines that form highly invasive tumors in nude mice. In contrast, the levels of IBP mRNA and protein were low or undetectable in normal human breast tissues, benign breast lesions or low-tumorigenic breast cancer cell lines. Over-expression of wild-type IBP in an IBP-negative breast cancer cell line markedly increased its proliferation and invasiveness in vitro. Conversely, RNA interference-mediated knockdown of IBP expression in an IBP-positive breast cancer cell line significantly reduced cell growth and invasiveness. Our results indicate that IBP is expressed in more highly invasive human breast cancer cells, such as MCF-7 and MDA-MB-231, with lower expression in normal breast tissue, benign tumors and less aggressive breast cancer cells, such as SKBR3 and MDA-MB-453. Thus, expression of IBP is correlated with the degree of malignant breast tumors. Nevertheless, it should be pointed our that further study with more tumor types is required to fully elucidate the role of IBP in tumorigenesis and the potential of IBP as a marker for more highly malignant tumors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19393345     DOI: 10.1016/j.intimp.2009.04.008

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  11 in total

1.  Tumor-associated antigens identified early in mouse mammary tumor development can be effective vaccine targets.

Authors:  Sasha E Stanton; Ekram Gad; Lauren R Corulli; Hailing Lu; Mary L Disis
Journal:  Vaccine       Date:  2019-05-21       Impact factor: 3.641

2.  Overexpression and gender-specific differences of SRC-3 (SRC-3/AIB1) immunoreactivity in human non-small cell lung cancer: an in vivo study.

Authors:  Haidong Wang; Dongmei Zhang; Wei Wu; Jiqiang Zhang; Deyu Guo; Qingliang Wang; Tao Jing; Chengping Xu; Xiuwu Bian; Kang Yang
Journal:  J Histochem Cytochem       Date:  2010-09-17       Impact factor: 2.479

3.  Overexpression and clinical significance of IBP in epithelial ovarian carcinoma.

Authors:  Yingjuan Xu; Yangming Hou; Tianbo Liu; Ge Lou
Journal:  Oncol Lett       Date:  2018-02-27       Impact factor: 2.967

4.  Interferon regulatory factor 4 binding protein is a novel p53 target gene and suppresses cisplatin-induced apoptosis of breast cancer cells.

Authors:  Mingzhen Yang; Fang Yuan; Peng Li; Zhongjiao Chen; An Chen; Shuhui Li; Chuanmin Hu
Journal:  Mol Cancer       Date:  2012-08-13       Impact factor: 27.401

5.  IBP-mediated suppression of autophagy promotes growth and metastasis of breast cancer cells via activating mTORC2/Akt/FOXO3a signaling pathway.

Authors:  S Chen; Q Han; X Wang; M Yang; Z Zhang; P Li; A Chen; C Hu; S Li
Journal:  Cell Death Dis       Date:  2013-10-10       Impact factor: 8.469

6.  Identification of novel targets for antiangiogenic therapy by comparing the gene expressions of tumor and normal endothelial cells.

Authors:  Tsuguteru Otsubo; Yasuhiro Hida; Noritaka Ohga; Hideshi Sato; Toshihiro Kai; Yasushi Matsuki; Hideo Takasu; Kosuke Akiyama; Nako Maishi; Taisuke Kawamoto; Nobuo Shinohara; Katsuya Nonomura; Kyoko Hida
Journal:  Cancer Sci       Date:  2014-04-19       Impact factor: 6.716

7.  DEF6 expression in ovarian carcinoma correlates with poor patient survival.

Authors:  Phui-Ly Liew; Chih-Yeu Fang; Yu-Chieh Lee; Yi-Chih Lee; Chi-Long Chen; Jan-Show Chu
Journal:  Diagn Pathol       Date:  2016-08-03       Impact factor: 2.644

8.  Identification of a Novel Alternatively Spliced Form of Inflammatory Regulator SWAP-70-Like Adapter of T Cells.

Authors:  Marie Hashimoto; Jun-Ichi Nagao; Shojiro Ikezaki; Sonoko Tasaki; Ken-Ichi Arita-Morioka; Yuka Narita; Tamaki Cho; Kenji Yuasa; Amnon Altman; Yoshihiko Tanaka
Journal:  Int J Inflam       Date:  2017-04-24

9.  Increased DEF6 expression is correlated with metastasis and poor prognosis in human osteosarcoma.

Authors:  Qiao Zhang; Guo-Sheng Zhao; Ya Cao; Xue-Feng Tang; Qiu-Lin Tan; Lu Lin; Qiao-Nan Guo
Journal:  Oncol Lett       Date:  2020-06-17       Impact factor: 2.967

10.  IBP regulates epithelial-to-mesenchymal transition and the motility of breast cancer cells via Rac1, RhoA and Cdc42 signaling pathways.

Authors:  Z Zhang; M Yang; R Chen; W Su; P Li; S Chen; Z Chen; A Chen; S Li; C Hu
Journal:  Oncogene       Date:  2013-08-26       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.